SCHEMBL718929

SCHEMBL718929

CCOC(=O)CCN(C)C(=O)c1ccc(NC(c2oc3ccc(F)cc3c2C)C2CCCCC2)nc1.Cc1c(C(Nc2ccc(C(=O)N(C)CCC(=O)O)cn2)C2CCCCC2)oc2ccc(F)cc12

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCG P01275 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SSTR5 P35346 1/20 0.32
IDH1 O75874 1/20 0.32
AKR1C3 P42330 2/20 0.31
EPHX2 P34913 1/20 0.31
CDK1 P06493 1/20 0.31
CDK2 P24941 1/20 0.31
THRB P10828 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716992 0.98 RAB9A (0.38) GCGNPC1RAB9AMEN1KMT2A
SCHEMBL719112 0.94 NPC1 (0.41) GCGNPC1RAB9AAKR1C3EPHX2
SCHEMBL10284459 0.89 RAB9A (0.41) GCGNPC1RAB9AMEN1KMT2A
SCHEMBL718020 0.88 NPC1 (0.38) GCGNPC1RAB9ATHRBTDP1
SCHEMBL716825 0.87 NPC1 (0.41) NPC1RAB9AMEN1KMT2AIDH1
SCHEMBL718275 0.86 RAB9A (0.40) NPC1RAB9AMEN1KMT2AIDH1
SCHEMBL717908 0.85 RAB9A (0.39) NPC1RAB9ATHRBTDP1KDM4E
SCHEMBL718443 0.85 MEN1 (0.46) GCGNPC1RAB9AMEN1KMT2A
SCHEMBL720374 0.84 GCG (0.40) GCGAKR1C3EPHX2CDK1CDK2
SCHEMBL719224 0.83 NPC1 (0.44) GCGNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP GCG 35/4885NPC1 902/4885RAB9A 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.